These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21525888)

  • 21. Uncorking the biomanufacturing bottleneck.
    Dove A
    Nat Biotechnol; 2002 Aug; 20(8):777-9. PubMed ID: 12148000
    [No Abstract]   [Full Text] [Related]  

  • 22. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative evaluation of alpha-galactosidase A infusions for treatment of Fabry disease.
    Hopkin RJ; Bissler J; Grabowski GA
    Genet Med; 2003; 5(3):144-53. PubMed ID: 12792421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 25. The scope of mycoplasma contamination within the biopharmaceutical industry.
    Armstrong SE; Mariano JA; Lundin DJ
    Biologicals; 2010 Mar; 38(2):211-3. PubMed ID: 20362237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mads Krogsgaard Thomsen. Interview by Asher Mullard.
    Thomsen MK
    Nat Rev Drug Discov; 2014 Feb; 13(2):96-7. PubMed ID: 24481301
    [No Abstract]   [Full Text] [Related]  

  • 27. New products highlight ambiguity of orphan drug law.
    Reid B
    Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
    [No Abstract]   [Full Text] [Related]  

  • 28. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks.
    Prazeres DM; Ferreira GN; Monteiro GA; Cooney CL; Cabral JM
    Trends Biotechnol; 1999 Apr; 17(4):169-74. PubMed ID: 10203776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The state of biopharmaceutical manufacturing.
    Molowa DT; Mazanet R
    Biotechnol Annu Rev; 2003; 9():285-302. PubMed ID: 14650933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-making plant blooms.
    Maxmen A
    Nature; 2012 May; 485(7397):160. PubMed ID: 22575938
    [No Abstract]   [Full Text] [Related]  

  • 31. [Fabry disease].
    Jakubowska E; Ryba M; Hruby Z
    Przegl Lek; 2006; 63(4):218-9. PubMed ID: 17080745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extractables from integrated single-use systems in biopharmaceutical manufacturing. Part I. Study on components (Pall Kleenpak connector and Kleenpak filter capsule).
    Ding W; Nash R
    PDA J Pharm Sci Technol; 2009; 63(4):322-38. PubMed ID: 20088246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 34. First treatment for Fabry's disease.
    FDA Consum; 2003; 37(4):4. PubMed ID: 12971327
    [No Abstract]   [Full Text] [Related]  

  • 35. Agalsidase beta (Fabrazyme) for Fabry disease.
    Med Lett Drugs Ther; 2003 Sep; 45(1165):74-5. PubMed ID: 12968124
    [No Abstract]   [Full Text] [Related]  

  • 36. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 37. Agalsidase: a second look. With hindsight: full data challenge efficacy.
    Prescrire Int; 2003 Oct; 12(67):168-71. PubMed ID: 14619828
    [No Abstract]   [Full Text] [Related]  

  • 38. A special report on India's biotech scenario: advancement in biopharmaceutical and health care sectors.
    Chakraborty C; Agoramoorthy G
    Biotechnol Adv; 2010; 28(1):1-6. PubMed ID: 19931371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme therapy for Fabry patients in jeopardy.
    Silversides A
    CMAJ; 2009 Sep; 181(6-7):E120. PubMed ID: 19752137
    [No Abstract]   [Full Text] [Related]  

  • 40. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.